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Purpose of the study
Maraviroc (MVC), a CCR5 antagonist, does not appear
to adversely affect serum lipids and may decrease LDL
cholesterol in dyslipidemic subjects. The CCR5-del32
polymorphism, resulting in reduced (heterozygous) or
absent (homozygous) CCR5 expression, is associated
with reduced risk of cardiovascular disease. An early
imbalance of cardiovascular adverse events was noted in
the MVC phase 2b development program at 24 weeks.
We investigated the longer term risk of cardiovascular
events in MVC recipients in the development program.
The D:A:D study and other cohorts have reported an
incidence of 3.6/1000 PY for myocardial infarction (MI)
among patients on HAART.
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Ischemic cardiovascular adverse events among patients
treated in MERIT (MVC versus efavirenz [EFV] in treat-
ment-naïve [TN] patients), MOTIVATE (MVC versus
placebo [PBO] in treatment-experienced [TE] patients),
and study 1029 (MVC versus PBO in non-R5, TE
patients) were prospectively collected. Incidence rates
and exposure-adjusted incidence rates (/100PY) were
compared to those of comparator regimens or existing
cohort data.
Summary of results
Conclusions
Rates of ischemic cardiovascular events were similar in
TN patients treated with either MVC or EFV. In TE
patients, the rate in the MVC arm was low and there
were no events in the PBO arm. However, exposure to
maraviroc was much greater than PBO in the TE popu-
lation, and most events occurred in individuals with
known cardiovascular risk factors. There were no addi-
tional patients with MI beyond the first 24 weeks
among TE patients. Rates of MI in the TE population
(1.0/1000PY) were consistent with published rates from
prospective cohort studies.
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